REMS Abuse Website: Celgene, Actelion Top List Of Suspected 'Gamers'
Executive Summary
Other sponsors could be using tactics other than REMS abuse to game the system, US FDA Commissioner Scott Gottlieb says.
You may also be interested in...
Drug Safety Patent Fight: Avadel Sues US FDA Over Interpretation Of Xyrem REMS Patent Use Code
Avadel challenges FDA requirement that it submit patent certification, asks court to direct the agency to issue final approval of its narcolepsy drug Lymryz. Having often criticized the use of REMS to delay competition, FDA now finds itself defending an Orange Book listing.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.
US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches
Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.